Innovus Pharma Announces the Launch of its Product Vesele® in Canada
May 17 2018 - 10:41AM
InvestorsHub NewsWire
Innovus Pharma Announces the Launch of its
Product Vesele® in Canada
Vesele® is the Seventh Innovus Pharma Product
launched in Canada to Date
San
Diego, CA -- May 17, 2018 -- InvestorsHub NewsWire -- Innovus
Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an
emerging commercial-stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine and
consumer care products to improve men’s and women's health and
respiratory diseases, today announced the launch of its product
Vesele®, approved by Health Canada for the increase in vasodilation
through nitric oxide production, in Canada. Vesele® is available in
that country directly through the Company’s website and through its
Beyond HumanÔ marketing and sales
platform.
“We
are very happy to announce the launch of Veseleâ
in Canada,” said Dr. Bassam Damaj,
the President and Chief Executive Officer of Innovus Pharma.
“Vesele® represents the third product launched through our
own sales and marketing commercial efforts in Canada in addition to
Apeaz® and Xyralid® and is our seventh product on the Canadian
market including Zestra®, Zestra Glide® and Uxor™ (EjectDelay™)
marketed by Orimed Pharma and UriVarx® through our partnership with
Acerus Pharmaceuticals Corporation.”
About Vesele®
Vesele® is approved by Health Canada as a Natural Health Product
(“NHP”) to increase vasodilation through nitric oxide production.
Vasodilation is the main mechanism used by many approved drugs
including Viagra and Cialis and others for erectile
dysfunction. Vesele® is a proprietary clinically tested oral
formulation of L-Arginine and L-Citrulline with the natural
absorption enhancer Bioperine® in patients suffering from sexual
dysfunction. Vesele® was formulated to increase blood flow and
nitric oxide production.
As
previously reported, a U.S. human clinical use survey was completed
on Vesele® to evaluate erectile dysfunction and sexual satisfaction
in men using Vesele® twice daily for up to four months with the
following favorable results:
1. 49.5%
increase in erection hardness
2. 44.5% increase in erection maintenance
3. 34.6% increase in desire for sexual activity
4. 34.1% increase the ability to satisfy the
partner
About Innovus Pharmaceuticals,
Inc.
Headquartered in San Diego, Innovus Pharma is an
emerging OTC consumer goods and specialty pharmaceutical
company engaged in the commercialization, licensing and development
of safe and effective non-prescription medicine and consumer care
products to improve men’s and women’s health and vitality and
respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health
solutions through its (a) OTC medicines and consumer and health
products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and
therapists, and (c) directly to consumers through our on-line
channels, retailers and wholesalers. The Company is dedicated to
being a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products. The Company is
actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx)
to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; and
www.diabsens.com.
Innovus Pharma's Forward-Looking
Safe Harbor:
Statements under the Private
Securities Litigation Reform Act, as amended: with the exception of
the historical information contained in this release, the matters
described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact
the matters herein described for a variety of reasons that are
outside the control of the Company, including, but not limited to,
projected revenues from the Vesele® product in Canada, estimated
market for its products, and statements about achieving its other
development, growth, commercialization, financial and
staffing objectives. Readers are cautioned not to place undue
reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company's most recent filing
on Form S-1, annual report on Form 10-K, subsequent quarterly
reports filed on Form 10-Q and other filings made with the SEC.
Copies of these reports are available from the SEC's website or
without charge from the Company.
Contact:
Randy Berholtz
Innovus Pharma Investor
Relations
Tel: +1 858 249 7865
ir@innovuspharma.com